[{"to": "60", "prefix": "Abstract\nAims\n\nTo examine in vivo the effect of ", "from": "49", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-meth"}, {"to": "319", "prefix": " received ", "from": "308", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " 200 mg or placebo twice daily for 7 days, and rosuvastatin "}, {"to": "602", "prefix": "o 96 h postdose.\n\nResults\n\nFollowing coadministration with ", "from": "591", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ", rosuvastatin geometric least square mean AUC"}, {"to": "957", "prefix": " of the total inhibitors. ", "from": "946", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " did not affect the proportion of circulating active or tota"}, {"to": "1099", "prefix": "s accounted for by circulating rosuvastatin.\n\nConclusions\n\n", "from": "1088", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " did not produce any change in rosuvastatin pharmacokinetics"}, {"to": "1338", "prefix": "tes to the elimination of rosuvastatin.\n\nKeywords: CYP3A4, ", "from": "1327", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ", P-glycoprotein, rosuvastatin\nGo to:\nIntroduction\nRosuvasta"}, {"to": "3748", "prefix": "y, the present study was conducted to assess the effect of ", "from": "3737", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " "}, {"to": "3836", "prefix": " on the pharmacokinetics of rosuvastatin.\n\n", "from": "3825", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " is also known to inhibit the activity of transport protein "}, {"to": "6024", "prefix": " Volunteers were randomized to receive daily oral doses of ", "from": "6013", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " 400 mg "}, {"to": "6336", "prefix": " with the morning dose of ", "from": "6325", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo. Volunteers then remained in the Clinical Pharma"}, {"to": "7308", "prefix": "ples were taken before administration of the first dose of ", "from": "7297", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo on day 1 of the second dosing period. Blood samp"}, {"to": "10874", "prefix": ", respectively.\n\nDetermination of ", "from": "10863", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " plasma concentrations\n\nBlood samples "}, {"to": "11000", "prefix": "n before and 2 h after administration of the first dose of ", "from": "10989", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo on days 4, 5, 6 and 7 of each dosing period. Blo"}, {"to": "11842", "prefix": " of rosuvastatin after dosing with ", "from": "11831", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " compared with placebo. If less than 12 volunteers had AUC d"}, {"to": "12388", "prefix": "CoA reductase inhibitors, and plasma drug concentration of ", "from": "12377", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " before and 2 h after administration of the first dose on da"}, {"to": "13121", "prefix": " ", "from": "13110", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ""}, {"to": "14224", "prefix": "ime were similar when rosuvastatin was coadministered with ", "from": "14213", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " and placebo "}, {"to": "14673", "prefix": "he assessment of exposure. Following coadministration with ", "from": "14662", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ", rosuvastatin glsmean AUC"}, {"to": "14887", "prefix": "1.43, so it was concluded that ", "from": "14876", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " had no effect on the pharmacokinetics of rosuvastatin.\n\nFig"}, {"to": "15062", "prefix": "rations of rosuvastatin over time when coadministered with ", "from": "15051", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " or placebo. "}, {"to": "15105", "prefix": " ", "from": "15094", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": "; "}, {"to": "15328", "prefix": " and Cmax of rosuvastatin, when coadministered with ", "from": "15317", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " and placebo\nComparison of areas under the plasma concentrat"}, {"to": "15821", "prefix": ". ", "from": "15810", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " did not affect the proportion of circulating active or tota"}, {"to": "16141", "prefix": "statin over time when rosuvastatin was coadministered with ", "from": "16130", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ". A similar pattern was seen when rosuvastatin was coadminis"}, {"to": "16275", "prefix": ", ...\nThe gmean plasma concentrations of ", "from": "16264", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " before administration of the first dose on days 4"}, {"to": "16501", "prefix": "tained during sampling. The gmean plasma concentrations of ", "from": "16490", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " 2 h after administration of the first dose on days 4"}, {"to": "16701", "prefix": "ons fell within the range anticipated for a 200-mg dose of ", "from": "16690", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ".\n\nRosuvastatin and ketoconazole were well tolerated when co"}, {"to": "16733", "prefix": "pated for a 200-mg dose of ketoconazole.\n\nRosuvastatin and ", "from": "16722", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " were well tolerated when coadministered. There were no seri"}, {"to": "17040", "prefix": "nistration of rosuvastatin and the potent CYP3A4 inhibitor ", "from": "17029", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " did not produce any change in pharmacokinetics of the forme"}, {"to": "17153", "prefix": "etics of the former. Furthermore, the results suggest that ", "from": "17142", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " had no effect on the systemic clearance of rosuvastatin, as"}, {"to": "19354", "prefix": "on for, or induction or inhibition of, transport proteins. ", "from": "19343", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "Ketoconazole", "suffix": " is known to have inhibitory effects on the transport protei"}, {"to": "19786", "prefix": "exposure would be expected following coadministration with ", "from": "19775", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": ". The potency of ketoconazole to inhibit P-gp has been asses"}, {"to": "19815", "prefix": "llowing coadministration with ketoconazole. The potency of ", "from": "19804", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " to inhibit P-gp has been assessed in cell-based assays and "}, {"to": "19981", "prefix": "sed on these data, it is likely that the concentrations of ", "from": "19970", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " achieved in the present study would have caused a degree of"}, {"to": "20322", "prefix": "netics of the P-gp substrate digoxin [21].\n\nIn conclusion, ", "from": "20311", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " did not affect the pharmacokinetics of rosuvastatin in heal"}, {"to": "20439", "prefix": "statin in healthy subjects. Therefore, coadministration of ", "from": "20428", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " and rosuvastatin is unlikely to increase the risk of toxici"}, {"to": "21005", "prefix": " for performing the ", "from": "20994", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "PMC1884190", "exact": "ketoconazole", "suffix": " assays, Olise M. Nwose MB BS for his support of this trial,"}, {"to": "100", "prefix": "vivo the effect of ketoconazole on the pharmacokinetics of ", "from": "89", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", a 3-hydroxy-3-methylglutaryl coenzyme A "}, {"to": "378", "prefix": "ketoconazole 200 mg or placebo twice daily for 7 days, and ", "from": "367", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " 80 mg was coadministered on day 4 of dosing. Plasma concent"}, {"to": "461", "prefix": "oadministered on day 4 of dosing. Plasma concentrations of ", "from": "450", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", and active and total HMG-CoA reductase inhibitors were mea"}, {"to": "616", "prefix": "e.\n\nResults\n\nFollowing coadministration with ketoconazole, ", "from": "605", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " geometric least square mean AUC"}, {"to": "817", "prefix": ". ", "from": "806", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " accounted for essentially all of the circulating active HMG"}, {"to": "1071", "prefix": "ng active or total inhibitors accounted for by circulating ", "from": "1060", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nConclusions\n\nKetoconazole did not produce any change in r"}, {"to": "1142", "prefix": ".\n\nConclusions\n\nKetoconazole did not produce any change in ", "from": "1131", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " pharmacokinetics in healthy subjects. The data suggest that"}, {"to": "1305", "prefix": " P-gp-mediated transport contributes to the elimination of ", "from": "1294", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nKeywords: CYP3A4, ketoconazole, P-glycoprotein, rosuvasta"}, {"to": "1368", "prefix": "vastatin.\n\nKeywords: CYP3A4, ketoconazole, P-glycoprotein, ", "from": "1357", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": "\nGo to:\nIntroduction\nRosuvastatin "}, {"to": "1401", "prefix": "conazole, P-glycoprotein, rosuvastatin\nGo to:\nIntroduction\n", "from": "1390", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " "}, {"to": "1410", "prefix": "", "from": "1404", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Crestor", "suffix": ""}, {"to": "1644", "prefix": "atment of patients with dyslipidaemia. In clinical trials, ", "from": "1633", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "1825", "prefix": " and was well-tolerated [1].\n\nThe pharmacokinetics of ", "from": "1814", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " following single- and multiple-dose administration of the d"}, {"to": "2332", "prefix": " the elimination half-life was about 20 h.\n\nElimination of ", "from": "2321", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " is primarily via the liver. In a clinical trial [3], 90% of"}, {"to": "2454", "prefix": "], 90% of an orally administered dose of 14C-radiolabelled ", "from": "2443", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was recovered in faeces as unchanged drug, a result consist"}, {"to": "2683", "prefix": "es and hepatocytes demonstrated only limited metabolism of ", "from": "2672", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " [4], and cytochrome P450 2C9 "}, {"to": "2842", "prefix": " with minor roles for CYP3A4 and CYP2C19 [4]. In addition, ", "from": "2831", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " had no significant inhibitory effect on the major CYP isofo"}, {"to": "3576", "prefix": "3A4 metabolism is not an important clearance mechanism for ", "from": "3565", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", an in vivo interaction with coadministered drugs that inhi"}, {"to": "3821", "prefix": " on the pharmacokinetics of ", "from": "3810", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nKetoconazole is also known to inhibit the activity of tra"}, {"to": "4032", "prefix": "esses may have a role in the absorption and disposition of ", "from": "4021", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ". Thus, studies with rats have demonstrated selective hepati"}, {"to": "4116", "prefix": "es with rats have demonstrated selective hepatic uptake of ", "from": "4105", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " by an active transport process [17], and rosuvastatin was s"}, {"to": "4170", "prefix": "e of rosuvastatin by an active transport process [17], and ", "from": "4159", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was shown to be a ligand for a liver-specific human organic"}, {"to": "4527", "prefix": "dication of whether P-gp-mediated transport contributes to ", "from": "4516", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " disposition.\n\nGo to:\nMethods\nThis trial was conducted in ac"}, {"to": "5679", "prefix": "", "from": "5668", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "6260", "prefix": "dosing period, volunteers were given a single oral dose of ", "from": "6249", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " 80 mg "}, {"to": "6639", "prefix": "the first dose on day 1 until 96 h after administration of ", "from": "6628", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " in each dosing period"}, {"to": "6817", "prefix": "m midnight before day 1 until 96 h after administration of ", "from": "6806", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " in each dosing period"}, {"to": "6994", "prefix": ".\n\nDetermination of ", "from": "6983", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " plasma concentrations\n\nBlood samples "}, {"to": "7055", "prefix": " for ", "from": "7044", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " assay were taken before administration of rosuvastatin on d"}, {"to": "7110", "prefix": "for rosuvastatin assay were taken before administration of ", "from": "7099", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8"}, {"to": "7797", "prefix": " [19]. Briefly, ", "from": "7786", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was extracted from the samples by automated solid-phase ext"}, {"to": "8286", "prefix": ". ", "from": "8275", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " was detected using a PE-Sciex API 365 triple quadruple mass"}, {"to": "8452", "prefix": " of ", "from": "8441", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was verified as 0.1 ng ml"}, {"to": "8704", "prefix": " 20%. Correlation coefficients for ", "from": "8693", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " calibration curves were 0.996-0.999. Mean imprecision value"}, {"to": "9426", "prefix": "or total inhibition.\n\nThe blood samples taken for ", "from": "9415", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " assay were also used to obtain plasma for active and total "}, {"to": "10605", "prefix": "rd curve. Concentrations are reported as ng equivalents of ", "from": "10594", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " ml"}, {"to": "11811", "prefix": " of ", "from": "11800", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " after dosing with ketoconazole compared with placebo. If le"}, {"to": "12235", "prefix": " of ", "from": "12224", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", area under the plasma concentration-time curve and Cmax of"}, {"to": "13106", "prefix": "", "from": "13095", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "13134", "prefix": "", "from": "13123", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "13209", "prefix": " for ", "from": "13198", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " AUC [or AUC"}, {"to": "13453", "prefix": "erval, the absence of an interaction was assumed [20].\n\nAs ", "from": "13442", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " AUC [or AUC"}, {"to": "14146", "prefix": " plasma concentrations of ", "from": "14135", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " over time were similar when rosuvastatin was coadministered"}, {"to": "14187", "prefix": "concentrations of rosuvastatin over time were similar when ", "from": "14176", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was coadministered with ketoconazole and placebo "}, {"to": "14687", "prefix": "of exposure. Following coadministration with ketoconazole, ", "from": "14676", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " glsmean AUC"}, {"to": "14941", "prefix": "that ketoconazole had no effect on the pharmacokinetics of ", "from": "14930", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nFigure 1\nFigure 1\nGeometric mean plasma concentrations of"}, {"to": "15014", "prefix": "\nFigure 1\nFigure 1\nGeometric mean plasma concentrations of ", "from": "15003", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " over time when coadministered with ketoconazole or placebo."}, {"to": "15090", "prefix": ", ", "from": "15079", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " "}, {"to": "15122", "prefix": ", ", "from": "15111", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " "}, {"to": "15200", "prefix": "ebo.\nTable 1\nTable 1\nSummary pharmacokinetic parameters of ", "from": "15189", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", and results of the statistical analysis of the plasma AUC"}, {"to": "15289", "prefix": " and Cmax of ", "from": "15278", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", when coadministered with ketoconazole and placebo\nComparis"}, {"to": "15447", "prefix": "a concentration-time curves measured to a common point for ", "from": "15436", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " and active and total HMG-CoA reductase inhibitors indicated"}, {"to": "15583", "prefix": ", within the accuracy and precision s of the methods used, ", "from": "15572", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " accounted for essentially all of the circulating active inh"}, {"to": "15953", "prefix": " HMG-CoA reductase inhibitors accounted for by circulating ", "from": "15942", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nFigure 2\nFigure 2\nGeometric mean plasma concentrations of"}, {"to": "16076", "prefix": "tions of active and total HMG-CoA reductase inhibitors and ", "from": "16065", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " over time when rosuvastatin was coadministered with ketocon"}, {"to": "16104", "prefix": "G-CoA reductase inhibitors and rosuvastatin over time when ", "from": "16093", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was coadministered with ketoconazole. A similar pattern was"}, {"to": "16187", "prefix": "istered with ketoconazole. A similar pattern was seen when ", "from": "16176", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " was coadministered with placebo. "}, {"to": "16417", "prefix": "ndicated that steady state was achieved before dosing with ", "from": "16406", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " and was maintained during sampling. The gmean plasma concen"}, {"to": "16716", "prefix": " the range anticipated for a 200-mg dose of ketoconazole.\n\n", "from": "16705", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "Rosuvastatin", "suffix": " and ketoconazole were well tolerated when coadministered. T"}, {"to": "16995", "prefix": " during this trial.\n\nGo to:\nDiscussion\nCoadministration of ", "from": "16984", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " and the potent CYP3A4 inhibitor ketoconazole did not produc"}, {"to": "17209", "prefix": "at ketoconazole had no effect on the systemic clearance of ", "from": "17198", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", as individual plasma concentration profiles, including the"}, {"to": "17379", "prefix": ", were similar between dosing periods.\n\nIn contrast to ", "from": "17368", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", atorvastatin [5], simvastatin [6], and lovastatin [7] are "}, {"to": "17905", "prefix": "ncentrations were measured in this trial. The finding that ", "from": "17894", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " accounted for essentially all of the circulating active inh"}, {"to": "18114", "prefix": ". The finding that the active inhibitors, and therefore ", "from": "18103", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ", constituted the majority of the total inhibitors indicates"}, {"to": "18430", "prefix": "support for previous data indicating limited metabolism of ", "from": "18419", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " [3, 4].\n\nOther HMG-CoA reductase inhibitors have circulatin"}, {"to": "19535", "prefix": "esses may have a role in the absorption and disposition of ", "from": "19524", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " [17, 18]. The identity of the rosuvastatin transporters tha"}, {"to": "19578", "prefix": " disposition of rosuvastatin [17, 18]. The identity of the ", "from": "19567", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " transporters that interact with rosuvastatin has not been c"}, {"to": "19623", "prefix": "entity of the rosuvastatin transporters that interact with ", "from": "19612", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " has not been clearly defined, but if it were a P-gp substra"}, {"to": "19714", "prefix": "y defined, but if it were a P-gp substrate, an increase in ", "from": "19703", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " exposure would be expected following coadministration with "}, {"to": "20112", "prefix": " P-gp inhibition [16]. Therefore, our results suggest that ", "from": "20101", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " is not a ligand for P-gp. This finding is in agreement with"}, {"to": "20233", "prefix": "ement with the results of a study that showed no effect of ", "from": "20222", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " on the pharmacokinetics of the P-gp substrate digoxin [21]."}, {"to": "20374", "prefix": "usion, ketoconazole did not affect the pharmacokinetics of ", "from": "20363", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " in healthy subjects. Therefore, coadministration of ketocon"}, {"to": "20456", "prefix": " subjects. Therefore, coadministration of ketoconazole and ", "from": "20445", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " is unlikely to increase the risk of toxicity at therapeutic"}, {"to": "20538", "prefix": "y to increase the risk of toxicity at therapeutic doses of ", "from": "20527", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ". The data suggest that neither cytochrome P450 3A4 nor P-gp"}, {"to": "20664", "prefix": " P-gp-mediated transport contributes to the elimination of ", "from": "20653", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": ".\n\nGo to:\nAcknowledgments\nThe authors thank Quintiles Scotla"}, {"to": "20778", "prefix": " for performing the ", "from": "20767", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC1884190", "exact": "rosuvastatin", "suffix": " assays, Medical Research Laboratories "}, {"to": "1530", "prefix": " reductase, the rate-limiting enzyme in ", "from": "1520", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1884190", "exact": "cholesterol", "suffix": " biosynthesis, and is effective for the treatment of patient"}, {"to": "1747", "prefix": "icant dose-dependent reductions in low-density lipoprotein ", "from": "1737", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1884190", "exact": "cholesterol", "suffix": " "}, {"to": "3000", "prefix": "", "from": "2989", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " [5], simvastatin [6], and lovastatin [7]"}, {"to": "3268", "prefix": " CYP3A4 activity. It has been shown that the metabolism of ", "from": "3257", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " [8"}, {"to": "17393", "prefix": "ilar between dosing periods.\n\nIn contrast to rosuvastatin, ", "from": "17382", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " [5], simvastatin [6], and lovastatin [7] are cleared primar"}, {"to": "18799", "prefix": "s metabolites may be affected. For example, in the case of ", "from": "18788", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": ", following coadministration with itraconazole, the mean AUC"}, {"to": "18982", "prefix": " of ", "from": "18971", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1884190", "exact": "atorvastatin", "suffix": " acid and lactone was increased 3.2- and 4.1-fold, respectiv"}, {"to": "3017", "prefix": "atorvastatin [5], ", "from": "3007", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884190", "exact": "simvastatin", "suffix": " [6], and lovastatin [7]"}, {"to": "3288", "prefix": "10], ", "from": "3278", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884190", "exact": "simvastatin", "suffix": " [11, 12], and lovastatin [13, 14] is inhibited by erythromy"}, {"to": "17410", "prefix": "g periods.\n\nIn contrast to rosuvastatin, atorvastatin [5], ", "from": "17400", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1884190", "exact": "simvastatin", "suffix": " [6], and lovastatin [7] are cleared primarily by metabolism"}, {"to": "3037", "prefix": "atorvastatin [5], simvastatin [6], and ", "from": "3028", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884190", "exact": "lovastatin", "suffix": " [7]"}, {"to": "3313", "prefix": "10], simvastatin [11, 12], and ", "from": "3304", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884190", "exact": "lovastatin", "suffix": " [13, 14] is inhibited by erythromycin and itraconazole, lea"}, {"to": "17430", "prefix": "st to rosuvastatin, atorvastatin [5], simvastatin [6], and ", "from": "17421", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC1884190", "exact": "lovastatin", "suffix": " [7] are cleared primarily by metabolism involving CYP3A4 an"}, {"to": "3351", "prefix": "vastatin [11, 12], and lovastatin [13, 14] is inhibited by ", "from": "3340", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "PMC1884190", "exact": "erythromycin", "suffix": " and itraconazole, leading to increased serum"}, {"to": "3368", "prefix": ", and lovastatin [13, 14] is inhibited by erythromycin and ", "from": "3357", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1884190", "exact": "itraconazole", "suffix": ", leading to increased serum"}, {"to": "18845", "prefix": " the case of atorvastatin, following coadministration with ", "from": "18834", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1884190", "exact": "itraconazole", "suffix": ", the mean AUC"}, {"to": "5174", "prefix": "haematology, or urinalysis results, or if total bilirubin, ", "from": "5168", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC1884190", "exact": "alanine", "suffix": " aminotransferase, aspartate aminotransferase, alkaline phos"}, {"to": "6691", "prefix": ", the consumption of ", "from": "6684", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002110", "setId": "PMC1884190", "exact": "caffeine", "suffix": "-containing drinks"}, {"to": "7424", "prefix": "Blood samples were collected into tubes containing lithium ", "from": "7418", "name": "Heparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D006493", "setId": "PMC1884190", "exact": "heparin", "suffix": " anticoagulant and centrifuged within 30 min. Plasma was the"}, {"to": "7543", "prefix": "Plasma was then harvested from the samples, mixed 1:1 with ", "from": "7530", "name": "Sodium Acetate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/56443", "setId": "PMC1884190", "exact": "sodium acetate", "suffix": " buffer 0.1 m pH 4.0, and stored at "}, {"to": "9725", "prefix": "drug-related components were isolated from plasma by using ", "from": "9714", "name": "acetonitrile", "fullId": "http://purl.bioontology.org/ontology/MESH/C032159", "setId": "PMC1884190", "exact": "acetonitrile", "suffix": " : acetone "}, {"to": "9735", "prefix": "mponents were isolated from plasma by using acetonitrile : ", "from": "9729", "name": "Acetone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000096", "setId": "PMC1884190", "exact": "acetone", "suffix": " "}, {"to": "10313", "prefix": "s separated from the substrate, after lactonization to 14C-", "from": "10299", "name": "mevalonolactone", "fullId": "http://purl.bioontology.org/ontology/MESH/C015367", "setId": "PMC1884190", "exact": "mevalonolactone", "suffix": " by hydrochloric acid, on a small ion-exchange column. The e"}, {"to": "10437", "prefix": "which contained the 14C-", "from": "10423", "name": "mevalonolactone", "fullId": "http://purl.bioontology.org/ontology/MESH/C015367", "setId": "PMC1884190", "exact": "mevalonolactone", "suffix": ""}, {"to": "11112", "prefix": "period. Blood samples were collected into tubes containing ", "from": "11109", "name": "Edetic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D004492", "setId": "PMC1884190", "exact": "EDTA", "suffix": " anticoagulant and centrifuged. Plasma was then harvested fr"}, {"to": "20287", "prefix": "rosuvastatin on the pharmacokinetics of the P-gp substrate ", "from": "20281", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "PMC1884190", "exact": "digoxin", "suffix": " [21].\n\nIn conclusion, ketoconazole did not affect the pharm"}, {"to": "31", "prefix": "Abstract\nBackground: ", "from": "22", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "Nelfinavir", "suffix": ", an HIV protease inhibitor with numerous drug"}, {"to": "257", "prefix": "ociated dyslipidemia.\n\nObjective: To examine the effect of ", "from": "248", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " on pravastatin pharmacokinetics.\n\nDesign: Open-label study "}, {"to": "569", "prefix": "sampling for pharmacokinetics on day 3. Subjects took only ", "from": "560", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " 1250 mg twice daily on days 4"}, {"to": "648", "prefix": "15, subjects continued ", "from": "639", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " and reinitiated pravastatin. Plasma samples were collected "}, {"to": "1116", "prefix": "ons were also lower when pravastatin was administered with ", "from": "1107", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": ". Median values for the maximum plasma concentrations were 2"}, {"to": "1338", "prefix": "s 40.1%.\n\nConclusions: Coadministration of pravastatin and ", "from": "1329", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " led to a substantial reduction in pravastatin plasma concen"}, {"to": "1573", "prefix": " activity.\n\nKeywords: HIV infection, statins, pravastatin, ", "from": "1564", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": ", drug interactions\nGo to:\nIntroduction\nNelfinavir "}, {"to": "1623", "prefix": "astatin, nelfinavir, drug interactions\nGo to:\nIntroduction\n", "from": "1614", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "Nelfinavir", "suffix": " "}, {"to": "8727", "prefix": " coadminstration of ", "from": "8718", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": ". The 95% confidence intervals around the geometric means ar"}, {"to": "8866", "prefix": "e 1\nTable 1\nPravastatin pharmacokinetics parameters in the ", "from": "8857", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " arm "}, {"to": "10264", "prefix": "ly, even in this study, the short-course administration of ", "from": "10255", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134527", "setId": "PMC1459289", "exact": "nelfinavir", "suffix": " in healthy HIV-seronegative subjects was associated with a "}, {"to": "141", "prefix": "drug interactions, is associated with dyslipidemia. ", "from": "131", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " is the preferred statin prescribed for HIV-associated dysli"}, {"to": "272", "prefix": "idemia.\n\nObjective: To examine the effect of nelfinavir on ", "from": "262", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics.\n\nDesign: Open-label study in healthy HIV-"}, {"to": "463", "prefix": "up sites in the United States.\n\nMethods: Subjects received ", "from": "453", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " 40 mg daily and underwent intensive sampling for pharmacoki"}, {"to": "676", "prefix": "15, subjects continued nelfinavir and reinitiated ", "from": "666", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". Plasma samples were collected over 24 h for the calculatio"}, {"to": "752", "prefix": "ma samples were collected over 24 h for the calculation of ", "from": "742", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " area under the concentration"}, {"to": "979", "prefix": "r analysis. The median within-subject percentage change in ", "from": "969", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC was a decrease of 46.5%. Pravastatin maximum plasma con"}, {"to": "1020", "prefix": "centage change in pravastatin AUC was a decrease of 46.5%. ", "from": "1010", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " maximum plasma concentrations were also lower when pravasta"}, {"to": "1083", "prefix": "astatin maximum plasma concentrations were also lower when ", "from": "1073", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " was administered with nelfinavir. Median values for the max"}, {"to": "1323", "prefix": "ject decrease was 40.1%.\n\nConclusions: Coadministration of ", "from": "1313", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " and nelfinavir led to a substantial reduction in pravastati"}, {"to": "1384", "prefix": "avastatin and nelfinavir led to a substantial reduction in ", "from": "1374", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " plasma concentrations. Higher doses of pravastatin may need"}, {"to": "1435", "prefix": "tion in pravastatin plasma concentrations. Higher doses of ", "from": "1425", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " may need to be prescribed in order to achieve optimal lipid"}, {"to": "1561", "prefix": "ipid-lowering activity.\n\nKeywords: HIV infection, statins, ", "from": "1551", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ", nelfinavir, drug interactions\nGo to:\nIntroduction\nNelfinav"}, {"to": "2189", "prefix": "in exposure was also increased by CYP3A4 inhibitors [2,3]. ", "from": "2179", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " was likely to be safe when coadministered with ritonavir"}, {"to": "2332", "prefix": "use, instead of an increase, we observed a 50% decrease in ", "from": "2322", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " area under the concentration"}, {"to": "2420", "prefix": ". Although we also showed that ", "from": "2410", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " did not alter NFV pharmacokinetics, we did not examine the "}, {"to": "2508", "prefix": " pharmacokinetics, we did not examine the effect of NFV on ", "from": "2498", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics. More recently, we have demonstrated that "}, {"to": "2702", "prefix": "h is a CYP3A4 inducer, also reduced the plasma exposure of ", "from": "2692", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " [4].\n\nThe mechanism by which these drugs reduce plasma expo"}, {"to": "2781", "prefix": "e mechanism by which these drugs reduce plasma exposure to ", "from": "2771", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is unknown, but this drug"}, {"to": "2873", "prefix": "drug interaction is of concern because a reduction in ", "from": "2863", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " plasma concentration may adversely affect the drug's abilit"}, {"to": "3214", "prefix": " inhibitor of CYP3A4 but an inducer of other CYP isoforms. ", "from": "3204", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " metabolism is complex, utilizing both oxidative and conjuga"}, {"to": "3448", "prefix": "nes the hypothesis that NFV would have a similar effect on ", "from": "3438", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics as ritonavir"}, {"to": "3740", "prefix": "examine the effect of efavirenz on the pharmacokinetics of ", "from": "3730", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ", atorvastatin, and simvastatin and the effect of NFV on the"}, {"to": "3832", "prefix": "mvastatin and the effect of NFV on the pharmacokinetics of ", "from": "3822", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". The efavirenz"}, {"to": "3984", "prefix": "d here address the effect of NFVon the pharmacokinetics of ", "from": "3974", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". At the time of this study design, NFV was the most commonl"}, {"to": "4402", "prefix": "h December 2001.\n\nStudy design\n\nSubjects self-administered ", "from": "4392", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " 40 mg daily in the morning for the first 3 days and on the "}, {"to": "4484", "prefix": " in the morning for the first 3 days and on the fourth day ", "from": "4474", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " was administered under observation. Blood samples were obta"}, {"to": "4660", "prefix": ", 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for ", "from": "4650", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics. On days 4 through 12, subjects took NFV 1"}, {"to": "4822", "prefix": "n days 13 through 15, subjects continued NFV and restarted ", "from": "4812", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " with the morning dose of NFV. On day 16, pravastatin and NF"}, {"to": "4875", "prefix": "arted pravastatin with the morning dose of NFV. On day 16, ", "from": "4865", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " and NFV doses were administered under observation and sampl"}, {"to": "4978", "prefix": "under observation and samples were collected over 24 h for ", "from": "4968", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " pharmacokinetics. Fasting serum total cholesterol, triglyce"}, {"to": "5563", "prefix": "tudy and informed consent was obtained from all subjects.\n\n", "from": "5553", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " assay\n\nSamples for pravastatin plasma concentrations were a"}, {"to": "5594", "prefix": "btained from all subjects.\n\nPravastatin assay\n\nSamples for ", "from": "5584", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " plasma concentrations were analyzed by Advion Biosciences I"}, {"to": "5776", "prefix": "[2,4].\n\nStatistical analyses\n\nThe primary endpoint was the ", "from": "5766", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC from 0 to 24 h before and after coadministration of NFV"}, {"to": "6539", "prefix": ", was used to test the null hypothesis of no difference in ", "from": "6529", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " exposure before initiation of NFV versus after dosing to st"}, {"to": "6737", "prefix": "entrations of statins may be associated with toxicity [7]. ", "from": "6727", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " exposure when taken with NFV relative to when taken alone, "}, {"to": "7950", "prefix": ".\n\nPlots of time-specific geometric mean concentrations of ", "from": "7940", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " with and without NFV are shown in Fig. 1. Median pravastati"}, {"to": "8011", "prefix": "avastatin with and without NFV are shown in Fig. 1. Median ", "from": "8001", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC values on days 3 and 16 were 86.5 and 46.8 ng"}, {"to": "8318", "prefix": "0.65. ", "from": "8308", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " Cmax values were also lower when pravastatin was administer"}, {"to": "8363", "prefix": "0.65. Pravastatin Cmax values were also lower when ", "from": "8353", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " was administered with NFV. Median Cmax values were 27.9 and"}, {"to": "8586", "prefix": ".\n\nFig. 1\nFig. 1\nGeometric mean concentration of ", "from": "8576", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " at each scheduled sample time and under the two dosing cond"}, {"to": "8820", "prefix": "tervals around the geometric means are ...\nTable 1\nTable 1\n", "from": "8810", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " pharmacokinetics parameters in the nelfinavir arm "}, {"to": "9180", "prefix": " changes after 3 days of ", "from": "9170", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " administration were "}, {"to": "9360", "prefix": " 16, for a median difference in within-subject response to ", "from": "9350", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " of 28 mg"}, {"to": "9553", "prefix": "use the baseline LDL was increased by NFV. After 3 days of ", "from": "9543", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " administration, the median changes were "}, {"to": "9749", "prefix": " 16, for a median difference in within-subject response to ", "from": "9739", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " of 6.7% "}, {"to": "10369", "prefix": "l median increase in LDL.\n\n", "from": "10359", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "Pravastatin", "suffix": " has become the preferred statin because of its lack of sign"}, {"to": "10511", "prefix": "bolism by P4503A4 and results from studies suggesting that ", "from": "10501", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is safe and tolerable in patients taking potent antiretrovi"}, {"to": "10679", "prefix": "saquinavir decreased the ", "from": "10669", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " median AUC by 50% [2]. In this study, NFV administration to"}, {"to": "10788", "prefix": "NFV administration to steady state reduced the exposure to ", "from": "10778", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " by a median of 46.5%. Similarly, we have also demonstrated "}, {"to": "10893", "prefix": "e have also demonstrated that efavirenz reduces the AUC of ", "from": "10883", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " [4].This reduction in exposure may compromise the effective"}, {"to": "10972", "prefix": " reduction in exposure may compromise the effectiveness of ", "from": "10962", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " in patients taking certain PI drugs or efavirenz. Although "}, {"to": "11105", "prefix": " study was not adequately powered nor designed to evaluate ", "from": "11095", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": "'s effectiveness in lowering LDL, we did note a trend sugges"}, {"to": "11241", "prefix": "hat its effectiveness was reduced.\n\nThe mechanism by which ", "from": "11231", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " concentrations are reduced is not known. The metabolism of "}, {"to": "11312", "prefix": "concentrations are reduced is not known. The metabolism of ", "from": "11302", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is complex. Induction of non-CYP3A4 oxidation or glucuronid"}, {"to": "11427", "prefix": "n or glucuronidation may result in more rapid clearance of ", "from": "11417", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ". In addition, hepatic transporter OATP1B1 may participate i"}, {"to": "11616", "prefix": "es both CYP isoforms as well as some transporters, reduced ", "from": "11606", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " exposure by a mean of 30% without affecting Cmax [14]. Howe"}, {"to": "11771", "prefix": "s itraconazole and mibefradil had no significant effect on ", "from": "11761", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " AUC [15]. Gemfibrozil as well as ciclosporin have been show"}, {"to": "11856", "prefix": "ibrozil as well as ciclosporin have been shown to increase ", "from": "11846", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " exposure during concomitant administration, pointing to pro"}, {"to": "12078", "prefix": "of the mechanism, the implication is that effectiveness of ", "from": "12068", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " may be reduced.\n\nClinical studies of pravastatin for the tr"}, {"to": "12127", "prefix": "veness of pravastatin may be reduced.\n\nClinical studies of ", "from": "12117", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " for the treatment of HIV-associated dyslipidemia have shown"}, {"to": "12252", "prefix": "shown mixed results. For example, in a randomized trial of ", "from": "12242", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " versus fenofibrate for combined HIV-associated dyslipidemia"}, {"to": "12362", "prefix": "ociated dyslipidemia, only 36% of subjects receiving 40 mg ", "from": "12352", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " daily met the LDL goal "}, {"to": "12573", "prefix": "", "from": "12563", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " or bezafibrate"}, {"to": "12825", "prefix": "ides of 45.8%, 39.5%, and 41.2%, respectively, after 20 mg ", "from": "12815", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " daily for 12 months. Interestingly, 55% of subjects receivi"}, {"to": "12899", "prefix": "ly for 12 months. Interestingly, 55% of subjects receiving ", "from": "12889", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " had normal total cholesterol at 12 months. Benesic and coll"}, {"to": "13025", "prefix": "colleagues [20] reported results for patients treated with ", "from": "13015", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " or fluvastatin. In 13 pravastatin-treated subjects "}, {"to": "13059", "prefix": "or patients treated with pravastatin or fluvastatin. In 13 ", "from": "13049", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": "-treated subjects "}, {"to": "13105", "prefix": "11 taking 10 mg ", "from": "13095", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": ""}, {"to": "13274", "prefix": "reported. The reduction of LDL level was only 14.4% in the ", "from": "13264", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " group, without a significant reduction in triglycerides. No"}, {"to": "13603", "prefix": " account for variations in efficacy reported.\n\nIn summary, ", "from": "13593", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " remains the statin of choice in HIV-infected persons taking"}, {"to": "13807", "prefix": "n and atorvastatin. The observed near 50% reduction in the ", "from": "13797", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " median AUC and a trend toward less reduction in LDL when co"}, {"to": "13929", "prefix": " when coadministered with NFV suggest that higher doses of ", "from": "13919", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " may need to be prescribed to achieve optimal lipid-lowering"}, {"to": "14055", "prefix": "ring activity. It remains unclear what the optimal dose of ", "from": "14045", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " is to achieve maximal lipid-lowering activity safely in HIV"}, {"to": "14260", "prefix": "at greater improvements in lipid levels may be observed if ", "from": "14250", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " doses are adjusted in the setting of agents that are known "}, {"to": "14455", "prefix": " the safety, tolerability, and efficacy of higher doses of ", "from": "14445", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC1459289", "exact": "pravastatin", "suffix": " are warranted.\n\nGo to:\nAcknowledgements\nThe ACTG A5108 team"}, {"to": "1954", "prefix": "nown as statins. In a previous study, we demonstrated that ", "from": "1944", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1459289", "exact": "simvastatin", "suffix": " should not be used with ritonavir"}, {"to": "3771", "prefix": " on the pharmacokinetics of pravastatin, atorvastatin, and ", "from": "3761", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1459289", "exact": "simvastatin", "suffix": " and the effect of NFV on the pharmacokinetics of pravastati"}, {"to": "13738", "prefix": "retroviral therapy, given its safety profile compared with ", "from": "13728", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC1459289", "exact": "simvastatin", "suffix": " and atorvastatin. The observed near 50% reduction in the pr"}, {"to": "1988", "prefix": ", we demonstrated that simvastatin should not be used with ", "from": "1980", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "2246", "prefix": "Pravastatin was likely to be safe when coadministered with ", "from": "2238", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "3065", "prefix": "PI drugs in clinical use that is not usually combined with ", "from": "3057", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ", but NFV has a similar effect on the CYP enzymes as ritonav"}, {"to": "3127", "prefix": "onavir, but NFV has a similar effect on the CYP enzymes as ", "from": "3119", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": " in that it is an inhibitor of CYP3A4 but an inducer of othe"}, {"to": "3478", "prefix": "d have a similar effect on pravastatin pharmacokinetics as ", "from": "3470", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "10642", "prefix": " therapy [10]. In our previous study, we demonstrated that ", "from": "10634", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/85762", "setId": "PMC1459289", "exact": "ritonavir", "suffix": ""}, {"to": "1999", "prefix": "", "from": "1990", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": " because of the large increases in plasma concentrations fro"}, {"to": "2257", "prefix": "", "from": "2248", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": " because, instead of an increase, we observed a 50% decrease"}, {"to": "3489", "prefix": "", "from": "3480", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": ".\n\nGo to:\nMethods\nThe AIDS Clinical Trials Group "}, {"to": "10653", "prefix": "", "from": "10644", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83395", "setId": "PMC1459289", "exact": "saquinavir", "suffix": " decreased the pravastatin median AUC by 50% [2]. In this st"}, {"to": "2121", "prefix": "tions from inhibition of CYP3A4 metabolism [2]. Similarly, ", "from": "2110", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1459289", "exact": "atorvastatin", "suffix": " exposure was also increased by CYP3A4 inhibitors [2,3]. Pra"}, {"to": "3754", "prefix": "ffect of efavirenz on the pharmacokinetics of pravastatin, ", "from": "3743", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1459289", "exact": "atorvastatin", "suffix": ", and simvastatin and the effect of NFV on the pharmacokinet"}, {"to": "13755", "prefix": "py, given its safety profile compared with simvastatin and ", "from": "13744", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC1459289", "exact": "atorvastatin", "suffix": ". The observed near 50% reduction in the pravastatin median "}, {"to": "2626", "prefix": "ated that a non-nucleoside reverse transcriptase inhibitor ", "from": "2618", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": ", which is a CYP3A4 inducer, also reduced the plasma exposur"}, {"to": "3701", "prefix": "tudy. The primary objectives were to examine the effect of ", "from": "3693", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": " on the pharmacokinetics of pravastatin, atorvastatin, and s"}, {"to": "10862", "prefix": "median of 46.5%. Similarly, we have also demonstrated that ", "from": "10854", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": " reduces the AUC of pravastatin [4].This reduction in exposu"}, {"to": "11021", "prefix": "ness of pravastatin in patients taking certain PI drugs or ", "from": "11013", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "PMC1459289", "exact": "efavirenz", "suffix": ". Although our study was not adequately powered nor designed"}, {"to": "2961", "prefix": "ion may adversely affect the drug's ability to lower serum ", "from": "2951", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": " effectively. NFV is one of the few PI drugs in clinical use"}, {"to": "5028", "prefix": "24 h for pravastatin pharmacokinetics. Fasting serum total ", "from": "5018", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": ", triglycerides, and high density lipoprotein concentrations"}, {"to": "12735", "prefix": "rs, Calza and colleagues [19] reported reductions in total ", "from": "12725", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": ", LDL, and triglycerides of 45.8%, 39.5%, and 41.2%, respect"}, {"to": "12928", "prefix": "ly, 55% of subjects receiving pravastatin had normal total ", "from": "12918", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": " at 12 months. Benesic and colleagues [20] reported results "}, {"to": "13139", "prefix": ", a decrease in total ", "from": "13129", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC1459289", "exact": "cholesterol", "suffix": " levels "}, {"to": "7535", "prefix": "o had grade 2 gastrointestinal complaints, one had grade 3 ", "from": "7529", "name": "Alanine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000409", "setId": "PMC1459289", "exact": "alanine", "suffix": " aminotransferase and grade 2 aspartate aminotransferase on "}, {"to": "11533", "prefix": "13]. ", "from": "11526", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "PMC1459289", "exact": "Rifampin", "suffix": ", which induces both CYP isoforms as well as some transporte"}, {"to": "11715", "prefix": "ithout affecting Cmax [14]. However, the CYP3A4 inhibitors ", "from": "11704", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "PMC1459289", "exact": "itraconazole", "suffix": " and mibefradil had no significant effect on pravastatin AUC"}, {"to": "11730", "prefix": "Cmax [14]. However, the CYP3A4 inhibitors itraconazole and ", "from": "11721", "name": "Mibefradil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83213", "setId": "PMC1459289", "exact": "mibefradil", "suffix": " had no significant effect on pravastatin AUC [15]. Gemfibro"}, {"to": "11793", "prefix": "efradil had no significant effect on pravastatin AUC [15]. ", "from": "11783", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015248", "setId": "PMC1459289", "exact": "Gemfibrozil", "suffix": " as well as ciclosporin have been shown to increase pravasta"}, {"to": "11816", "prefix": "ant effect on pravastatin AUC [15]. Gemfibrozil as well as ", "from": "11806", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC1459289", "exact": "ciclosporin", "suffix": " have been shown to increase pravastatin exposure during con"}, {"to": "12271", "prefix": ". For example, in a randomized trial of pravastatin versus ", "from": "12261", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "PMC1459289", "exact": "fenofibrate", "suffix": " for combined HIV-associated dyslipidemia, only 36% of subje"}, {"to": "12588", "prefix": "pravastatin or ", "from": "12578", "name": "Bezafibrate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1525", "setId": "PMC1459289", "exact": "bezafibrate", "suffix": ""}, {"to": "13040", "prefix": " reported results for patients treated with pravastatin or ", "from": "13030", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC1459289", "exact": "fluvastatin", "suffix": ". In 13 pravastatin-treated subjects "}, {"to": "25", "prefix": "Abstract\nAIM\n\n", "from": "15", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": ", an oral, nonpeptide thrombopoietin receptor agonist, inhib"}, {"to": "630", "prefix": "fficacy and toxicity. To determine if co-administration of ", "from": "620", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin alters plasma rosuvastatin exposure, an o"}, {"to": "806", "prefix": "ult subjects.\n\nMETHODS\n\nSubjects received rosuvastatin and ", "from": "796", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9,"}, {"to": "878", "prefix": "rally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ", "from": "868", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily; day 10, eltrombopag 75 mg once daily and "}, {"to": "916", "prefix": "e dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ", "from": "906", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily and rosuvastatin 10 mg single dose. Advers"}, {"to": "1177", "prefix": "s 1 to 5 and days 10 to 14.\n\nRESULTS\n\nCo-administration of ", "from": "1167", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin increased geometric mean "}, {"to": "1484", "prefix": "sian subjects.\n\nCONCLUSIONS\n\nConcomitant administration of ", "from": "1474", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin was associated with increased rosuvastati"}, {"to": "1663", "prefix": "uctase inhibitors may be reduced by the concomitant use of ", "from": "1653", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". In subjects taking eltrombopag, a reduced dose of HMG Co-A"}, {"to": "1695", "prefix": " by the concomitant use of eltrombopag. In subjects taking ", "from": "1685", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", a reduced dose of HMG Co-A reductase inhibitors may be nee"}, {"to": "1806", "prefix": "hibitors may be needed.\n\nKeywords: BCRP, drug interaction, ", "from": "1796", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", OATP1B1, rosuvastatin\nWHAT IS ALREADY KNOWN ABOUT THIS SUB"}, {"to": "2006", "prefix": " is important for rosuvastatin absorption and elimination. ", "from": "1996", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " inhibits OATP1B1 and BCRP in vitro at clinically relevant c"}, {"to": "2261", "prefix": "dependent toxicities. To determine if co-administration of ", "from": "2251", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin alters plasma rosuvastatin exposure, an o"}, {"to": "2444", "prefix": "jects.\nWHAT THIS STUDY ADDS\n\nConcomitant administration of ", "from": "2434", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin was associated with increased rosuvastati"}, {"to": "2659", "prefix": "uctase inhibitors may be reduced by the concomitant use of ", "from": "2649", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". In subjects taking eltrombopag, a reduced dose of HMG Co-A"}, {"to": "2691", "prefix": " by the concomitant use of eltrombopag. In subjects taking ", "from": "2681", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", a reduced dose of HMG Co-A reductase inhibitors may be nee"}, {"to": "2787", "prefix": "-A reductase inhibitors may be needed.\nGo to:\nIntroduction\n", "from": "2777", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " "}, {"to": "3095", "prefix": "3]. ", "from": "3085", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " binds to the transmembrane domain of the thrombopoietin rec"}, {"to": "3299", "prefix": "rentiation of megakaryocytes [4].\n\nIn preclinical studies, ", "from": "3289", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " inhibited the organic anion transporting polypeptide 1B1 "}, {"to": "3423", "prefix": ". ", "from": "3413", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " was also identified as a BCRP substrate in vitro. OATP1B1 i"}, {"to": "4848", "prefix": " The objective of this study was to evaluate the impact of ", "from": "4838", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on plasma rosuvastatin exposure.\n\nGo to:\nMethods\nStudy desi"}, {"to": "5155", "prefix": "tten, informed consent. Subjects received rosuvastatin and ", "from": "5145", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " orally in the following sequence: day 1, rosuvastatin 10 mg"}, {"to": "5261", "prefix": "ay 1, rosuvastatin 10 mg single dose; day 6 through day 9, ", "from": "5251", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily; day 10, eltrombopag 75 mg once daily and "}, {"to": "5299", "prefix": "day 6 through day 9, eltrombopag 75 mg once daily; day 10, ", "from": "5289", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily and rosuvastatin 10 mg single dose. This s"}, {"to": "9880", "prefix": "ns. Plasma PK samples collected on day 10 were assayed for ", "from": "9870", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " using a validated analytical method based on protein precip"}, {"to": "10068", "prefix": "iquot of plasma, the lower limit of quantification for the ", "from": "10058", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " assay was 100 ng ml"}, {"to": "10762", "prefix": "suvastatin when administered alone or co-administered with ", "from": "10752", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". Cmax and the first time to reach Cmax "}, {"to": "11294", "prefix": " observed quantifiable concentration.\n\nSteady-state plasma ", "from": "11284", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " Cmax and AUC over a dosing interval "}, {"to": "11422", "prefix": "ated for the combination regimen only. In addition, plasma ", "from": "11412", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " trough concentrations collected on day 10 prior to administ"}, {"to": "11603", "prefix": "co-administration were measured.\n\nTo assess the effects of ", "from": "11593", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on rosuvastatin PK, log transformed plasma rosuvastatin AUC"}, {"to": "12056", "prefix": "o give point and interval estimates for the ratios. Plasma ", "from": "12046", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " and rosuvastatin PK parameters were summarized by treatment"}, {"to": "15556", "prefix": "acokinetics and treatment comparisons\nCo-administration of ", "from": "15546", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin increased plasma rosuvastatin AUC"}, {"to": "15757", "prefix": ". The impact of ", "from": "15747", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on plasma rosuvastatin exposure differed by race. Plasma ro"}, {"to": "16152", "prefix": " and by race for each treatment in Figure 1. The impact of ", "from": "16142", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " on plasma rosuvastatin exposure appeared to differ by gende"}, {"to": "16388", "prefix": " ", "from": "16378", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ""}, {"to": "17597", "prefix": "\nFor the overall population, the geometric mean of plasma ", "from": "17587", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " Cmax was 8.00 "}, {"to": "17674", "prefix": "1 h, and plasma ", "from": "17664", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures were similar between Asian and non-Asian subjects"}, {"to": "17894", "prefix": " with the c.421AA genotype had the highest plasma ", "from": "17884", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " AUC"}, {"to": "18096", "prefix": "ith the c.421CC genotype. When races were combined, plasma ", "from": "18086", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure was similar between males and females "}, {"to": "18240", "prefix": "non-Asian group, women had approximately 46% higher plasma ", "from": "18230", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " AUC"}, {"to": "18344", "prefix": " ", "from": "18334", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " trough concentrations of 2.98 "}, {"to": "18659", "prefix": "e dose of rosuvastatin.\n\nTable 5\nTable 5\nSummary of plasma ", "from": "18649", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " pharmacokinetics\nSafety\n\nAEs were reported by 10% to 21% of"}, {"to": "19132", "prefix": "e observed in several subjects following administration of ", "from": "19122", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". At the follow-up visit, 16 subjects "}, {"to": "19718", "prefix": "\nThis study was conducted because in vitro data identified ", "from": "19708", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " as an inhibitor of both OATP1B1 and BCRP with IC50s of 2.7 "}, {"to": "19808", "prefix": ". ", "from": "19798", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " concentrations achieved clinically are higher than this IC5"}, {"to": "20528", "prefix": "central finding of the study was that co-administration of ", "from": "20518", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " 75 mg once daily with a single dose of rosuvastatin 10 mg i"}, {"to": "21596", "prefix": "ers [14]. It was anticipated that inhibition of OATP1B1 by ", "from": "21586", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " would have a lesser effect on plasma rosuvastatin exposure "}, {"to": "23491", "prefix": "lunteers [15].\n\nBecause the in vitro inhibition potency of ", "from": "23481", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " is similar for OATP1B1 and BCRP and because genetic polymor"}, {"to": "23715", "prefix": "ble that the increased rosuvastatin exposure observed with ", "from": "23705", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " co-administration is due to inhibition of both transporters"}, {"to": "24439", "prefix": "bile acid uptake transporter NTCP [13]. It is not known if ", "from": "24429", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " has an impact on these other transporters.\n\nOATP1B1 is high"}, {"to": "25760", "prefix": " polymorphisms, the results of the ", "from": "25750", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": "-rosuvastatin interaction study may be extended to other sta"}, {"to": "25874", "prefix": "ded to other statins. In subjects who were co-administered ", "from": "25864", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " and rosuvastatin, increased rosuvastatin Cmax "}, {"to": "26109", "prefix": "ucing a subject's dose of statin when co-administered with ", "from": "26099", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". Monitoring side effects, clinical chemistry, and lipid con"}, {"to": "26232", "prefix": "pid concentrations is warranted in subjects receiving both ", "from": "26222", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " and a statin. As noted by other investigators, most clinica"}, {"to": "26472", "prefix": "tion and dosing [5].\n\nThe impact of rosuvastatin on plasma ", "from": "26462", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " PK was not formally assessed. However, eltrombopag trough c"}, {"to": "26523", "prefix": " plasma eltrombopag PK was not formally assessed. However, ", "from": "26513", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " trough concentrations collected prior to co-administration "}, {"to": "26741", "prefix": "tion of a single dose of rosuvastatin. In addition, plasma ", "from": "26731", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure for the 75 mg once daily regimen "}, {"to": "26889", "prefix": " was generally as expected based on plasma ", "from": "26879", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures observed in other eltrombopag studies [20"}, {"to": "26929", "prefix": "ed based on plasma eltrombopag exposures observed in other ", "from": "26919", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " studies [20"}, {"to": "27044", "prefix": "ppear to be a significant impact of rosuvastatin on plasma ", "from": "27034", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " PK.\n\nPlasma eltrombopag exposures collected in the presence"}, {"to": "27068", "prefix": "t impact of rosuvastatin on plasma eltrombopag PK.\n\nPlasma ", "from": "27058", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures collected in the presence of rosuvastatin were si"}, {"to": "27279", "prefix": "udies that have shown approximately two-fold higher plasma ", "from": "27269", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposures in Asian vs. non-Asian subjects [21, 22]. In thes"}, {"to": "27601", "prefix": "he non-Asian population, female subjects had higher plasma ", "from": "27591", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure, which is consistent with previous reports [22]. E"}, {"to": "27671", "prefix": " exposure, which is consistent with previous reports [22]. ", "from": "27661", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "Eltrombopag", "suffix": " is a BCRP substrate and plasma eltrombopag exposure was sim"}, {"to": "27714", "prefix": "s reports [22]. Eltrombopag is a BCRP substrate and plasma ", "from": "27704", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure was similar between c.421CC and c.421CA genotypes."}, {"to": "27873", "prefix": " with the c.421AA genotype had the highest plasma ", "from": "27863", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " AUC"}, {"to": "28169", "prefix": "rawn as to whether this genotype is associated with plasma ", "from": "28159", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " exposure.\n\nIn conclusion, concomitant administration of elt"}, {"to": "28237", "prefix": "ag exposure.\n\nIn conclusion, concomitant administration of ", "from": "28227", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": " with rosuvastatin was associated with increased rosuvastati"}, {"to": "28416", "prefix": "uctase inhibitors may be reduced by the concomitant use of ", "from": "28406", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ". In subjects taking eltrombopag, a reduced dose of HMG Co-A"}, {"to": "28448", "prefix": " by the concomitant use of eltrombopag. In subjects taking ", "from": "28438", "name": "eltrombopag", "fullId": "http://purl.bioontology.org/ontology/MESH/C520809", "setId": "PMC3162661", "exact": "eltrombopag", "suffix": ", a reduced dose of HMG Co-A reductase inhibitors may be nee"}, {"to": "255", "prefix": " in vitro. OATP1B1 is important for hepatic uptake of ", "from": "244", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and inhibition of this transporter could reduce cholesterol"}, {"to": "519", "prefix": "of this transporter could increase both hepatic and plasma ", "from": "508", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentrations, resulting in increased efficacy and toxicit"}, {"to": "648", "prefix": "ity. To determine if co-administration of eltrombopag with ", "from": "637", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alters plasma rosuvastatin exposure, an open-label study wa"}, {"to": "675", "prefix": "inistration of eltrombopag with rosuvastatin alters plasma ", "from": "664", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, an open-label study was conducted in 42 healthy a"}, {"to": "790", "prefix": " in 42 healthy adult subjects.\n\nMETHODS\n\nSubjects received ", "from": "779", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and eltrombopag orally: day 1, rosuvastatin 10 mg single do"}, {"to": "834", "prefix": "jects received rosuvastatin and eltrombopag orally: day 1, ", "from": "823", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose; days 6 to 9, eltrombopag 75 mg once dail"}, {"to": "950", "prefix": "75 mg once daily; day 10, eltrombopag 75 mg once daily and ", "from": "939", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose. Adverse event assessments were performed"}, {"to": "1195", "prefix": " 10 to 14.\n\nRESULTS\n\nCo-administration of eltrombopag with ", "from": "1184", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " increased geometric mean "}, {"to": "1266", "prefix": " plasma ", "from": "1255", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "1502", "prefix": "ONCLUSIONS\n\nConcomitant administration of eltrombopag with ", "from": "1491", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was associated with increased rosuvastatin exposure. The th"}, {"to": "1545", "prefix": "ltrombopag with rosuvastatin was associated with increased ", "from": "1534", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure. The therapeutic index of HMG Co-A reductase inhib"}, {"to": "1829", "prefix": ".\n\nKeywords: BCRP, drug interaction, eltrombopag, OATP1B1, ", "from": "1818", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": "\nWHAT IS ALREADY KNOWN ABOUT THIS SUBJECT\n\nOATP1B1 is import"}, {"to": "1927", "prefix": "T THIS SUBJECT\n\nOATP1B1 is important for hepatic uptake of ", "from": "1916", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and BCRP is important for rosuvastatin absorption and elimi"}, {"to": "1966", "prefix": "r hepatic uptake of rosuvastatin and BCRP is important for ", "from": "1955", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " absorption and elimination. Eltrombopag inhibits OATP1B1 an"}, {"to": "2279", "prefix": "ies. To determine if co-administration of eltrombopag with ", "from": "2268", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alters plasma rosuvastatin exposure, an open-label study wa"}, {"to": "2306", "prefix": "inistration of eltrombopag with rosuvastatin alters plasma ", "from": "2295", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, an open-label study was conducted in 42 healthy a"}, {"to": "2462", "prefix": "STUDY ADDS\n\nConcomitant administration of eltrombopag with ", "from": "2451", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was associated with increased rosuvastatin exposure via inh"}, {"to": "2505", "prefix": "ltrombopag with rosuvastatin was associated with increased ", "from": "2494", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure via inhibition of drug transporters. The therapeut"}, {"to": "3638", "prefix": " [5]. OATP1B1 is important for ", "from": "3627", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " disposition as demonstrated by genetic polymorphism, where "}, {"to": "3789", "prefix": " c.521CC genotype had 65% higher ", "from": "3778", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " mean area under the curve "}, {"to": "4046", "prefix": " has also been associated with higher plasma ", "from": "4035", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure [7]. BCRP is an efflux transporter that transports"}, {"to": "4216", "prefix": "o limits intestinal drug absorption. BCRP is important for ", "from": "4205", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " disposition as demonstrated by genetic polymorphism, where "}, {"to": "4403", "prefix": "omozygous c.421AA genotypes had approximately two-fold the ", "from": "4392", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "4633", "prefix": " cholesterol in subjects receiving ", "from": "4622", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " therapy [10].\n\nRosuvastatin has known transporter-mediated "}, {"to": "4661", "prefix": "lesterol in subjects receiving rosuvastatin therapy [10].\n\n", "from": "4650", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "Rosuvastatin", "suffix": " has known transporter-mediated drug interactions, such as i"}, {"to": "4871", "prefix": " study was to evaluate the impact of eltrombopag on plasma ", "from": "4860", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure.\n\nGo to:\nMethods\nStudy design\n\nAn open-label, sing"}, {"to": "5139", "prefix": "ects provided written, informed consent. Subjects received ", "from": "5128", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and eltrombopag orally in the following sequence: day 1, ro"}, {"to": "5209", "prefix": "n and eltrombopag orally in the following sequence: day 1, ", "from": "5198", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose; day 6 through day 9, eltrombopag 75 mg o"}, {"to": "5333", "prefix": "75 mg once daily; day 10, eltrombopag 75 mg once daily and ", "from": "5322", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg single dose. This study was designed and monitored in"}, {"to": "7204", "prefix": ", 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose ", "from": "7193", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " administration on days 1 and 10. A blood sample was obtaine"}, {"to": "9103", "prefix": "sma PK samples collected on days 1 and 10 were assayed for ", "from": "9092", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " using a validated analytical method based on solid phase ex"}, {"to": "9371", "prefix": "iquot of plasma, the lower limit of quantification for the ", "from": "9360", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " assay was 0.2 ng ml"}, {"to": "10702", "prefix": " of ", "from": "10691", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " when administered alone or co-administered with eltrombopag"}, {"to": "11504", "prefix": "centrations collected on day 10 prior to administration of ", "from": "11493", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " and 24 h after rosuvastatin co-administration were measured"}, {"to": "11532", "prefix": " 10 prior to administration of rosuvastatin and 24 h after ", "from": "11521", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " co-administration were measured.\n\nTo assess the effects of "}, {"to": "11619", "prefix": "on were measured.\n\nTo assess the effects of eltrombopag on ", "from": "11608", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK, log transformed plasma rosuvastatin AUC"}, {"to": "11659", "prefix": " of eltrombopag on rosuvastatin PK, log transformed plasma ", "from": "11648", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "12073", "prefix": " interval estimates for the ratios. Plasma eltrombopag and ", "from": "12062", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK parameters were summarized by treatment and by race and "}, {"to": "12177", "prefix": " treatment and by race and gender within treatment. Plasma ", "from": "12166", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentration"}, {"to": "12269", "prefix": "rofiles were plotted by treatment, race and gender. Plasma ", "from": "12258", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "12489", "prefix": "lyses. Similar to the primary statistical analysis, plasma ", "from": "12478", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK values were compared between treatments for subgroups ba"}, {"to": "12671", "prefix": "ivariate analyses of the relationship between day 1 plasma ", "from": "12660", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "14553", "prefix": " were retained as significant predictors of plasma ", "from": "14542", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "14803", "prefix": "ned in the final model as significant predictors of plasma ", "from": "14792", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "15135", "prefix": ". Asian participants had a 109% higher ", "from": "15124", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "15218", "prefix": "d a 139% higher Cmax compared with non-Asian subjects when ", "from": "15207", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was administered alone "}, {"to": "15333", "prefix": "e non-Asian population, female participants had 50% higher ", "from": "15322", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "15408", "prefix": " and 84% higher Cmax compared with male subjects when ", "from": "15397", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was administered alone.\n\nTable 4\nTable 4\nSummary of plasma "}, {"to": "15480", "prefix": "was administered alone.\n\nTable 4\nTable 4\nSummary of plasma ", "from": "15469", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " pharmacokinetics and treatment comparisons\nCo-administratio"}, {"to": "15574", "prefix": "reatment comparisons\nCo-administration of eltrombopag with ", "from": "15563", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " increased plasma rosuvastatin AUC"}, {"to": "15604", "prefix": "stration of eltrombopag with rosuvastatin increased plasma ", "from": "15593", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "15714", "prefix": "e overall study population compared with administration of ", "from": "15703", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alone "}, {"to": "15780", "prefix": ". The impact of eltrombopag on plasma ", "from": "15769", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure differed by race. Plasma rosuvastatin AUC"}, {"to": "15827", "prefix": "g on plasma rosuvastatin exposure differed by race. Plasma ", "from": "15816", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "16013", "prefix": ". Median plasma ", "from": "16002", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentration"}, {"to": "16175", "prefix": "treatment in Figure 1. The impact of eltrombopag on plasma ", "from": "16164", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure appeared to differ by gender within the non-Asian "}, {"to": "16302", "prefix": ".\n\nFigure 1\nFigure 1\nMedian plasma ", "from": "16291", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " concentration"}, {"to": "16809", "prefix": "3 had higher plasma ", "from": "16798", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures than subjects with scores of 0"}, {"to": "16911", "prefix": "1, and there was also a trend for higher plasma ", "from": "16900", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures for subjects in category 4 "}, {"to": "17109", "prefix": "ons regarding the relationship between genotype and plasma ", "from": "17098", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure. Plasma rosuvastatin AUC"}, {"to": "17139", "prefix": " between genotype and plasma rosuvastatin exposure. Plasma ", "from": "17128", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "17288", "prefix": "ng with race and gender details.\n\nFigure 2\nFigure 2\nPlasma ", "from": "17277", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " AUC"}, {"to": "18465", "prefix": " collected on day 10 prior to co-administration of ", "from": "18454", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " were similar to trough concentrations of 3.22 "}, {"to": "18611", "prefix": "collected 24 h after co-administration of a single dose of ", "from": "18600", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ".\n\nTable 5\nTable 5\nSummary of plasma eltrombopag pharmacokin"}, {"to": "19938", "prefix": ", and OATP1B1 and BCRP are important for ", "from": "19927", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " disposition. Statins are widely used cholesterol-lowering a"}, {"to": "20580", "prefix": "tion of eltrombopag 75 mg once daily with a single dose of ", "from": "20569", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " 10 mg increased plasma rosuvastatin Cmax by 103% and AUC"}, {"to": "20616", "prefix": " with a single dose of rosuvastatin 10 mg increased plasma ", "from": "20605", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " Cmax by 103% and AUC"}, {"to": "20708", "prefix": " by 55% in the overall study population compared with ", "from": "20697", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " alone "}, {"to": "20792", "prefix": ".\n\nBecause it was known that Asian subjects have higher ", "from": "20781", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures than non-Asian subjects [7], this study enrolled "}, {"to": "21009", "prefix": "revious data, Asian race was associated with higher plasma ", "from": "20998", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, with Asian subjects having approximately twice th"}, {"to": "21149", "prefix": "e as non-Asian subjects enrolled in the current study when ", "from": "21138", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was given alone. Interestingly, the non-Asian group studied"}, {"to": "21429", "prefix": "bjects. The observed interindividual variability in plasma ", "from": "21418", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure could be due to different genetic polymorphisms th"}, {"to": "21646", "prefix": "ATP1B1 by eltrombopag would have a lesser effect on plasma ", "from": "21635", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure in Asian subjects compared with non-Asian subjects"}, {"to": "22031", "prefix": " have not been associated with racial differences in ", "from": "22020", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK, but have been associated with rosuvastatin PK variabili"}, {"to": "22078", "prefix": "ferences in rosuvastatin PK, but have been associated with ", "from": "22067", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK variability in White subjects [7]. BCRP C421A polymorphi"}, {"to": "22180", "prefix": "ts [7]. BCRP C421A polymorphisms have been associated with ", "from": "22169", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " PK variability as well [8]. The study was not designed to s"}, {"to": "22530", "prefix": ", which have not been independently associated with plasma ", "from": "22519", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, were relatively evenly distributed across the enr"}, {"to": "22750", "prefix": "ely, genotype was not significantly associated with plasma ", "from": "22739", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure when race, gender and body weight were included in"}, {"to": "23002", "prefix": "ion between haplotype and genotype combinations and plasma ", "from": "22991", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure when race, gender and body weight were included in"}, {"to": "23247", "prefix": ".\n\nThe finding of statistically significant higher plasma ", "from": "23236", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposures in female subjects has not been reported in the l"}, {"to": "23623", "prefix": "hisms in both transporters are known to be associated with ", "from": "23612", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure, it is probable that the increased rosuvastatin ex"}, {"to": "23680", "prefix": "h rosuvastatin exposure, it is probable that the increased ", "from": "23669", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure observed with eltrombopag co-administration is due"}, {"to": "23828", "prefix": " both transporters. Inhibition of OATP1B1 increases plasma ", "from": "23817", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure by reducing the hepatic uptake; in this scenario, "}, {"to": "23900", "prefix": "exposure by reducing the hepatic uptake; in this scenario, ", "from": "23889", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " efficacy may be reduced and toxicity may be increased. In c"}, {"to": "24017", "prefix": "ncreased. In contrast, inhibition of BCRP increases plasma ", "from": "24006", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure by enhancing rosuvastatin absorption and"}, {"to": "24052", "prefix": "f BCRP increases plasma rosuvastatin exposure by enhancing ", "from": "24041", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " absorption and"}, {"to": "24097", "prefix": "or by inhibiting ", "from": "24086", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " elimination in the bile; in this scenario rosuvastatin effi"}, {"to": "24152", "prefix": "ing rosuvastatin elimination in the bile; in this scenario ", "from": "24141", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " efficacy and toxicity may both be increased. In vitro evide"}, {"to": "24247", "prefix": "ay both be increased. In vitro evidence also suggests that ", "from": "24236", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " is a substrate for other hepatic uptake transporters includ"}, {"to": "24910", "prefix": " 521CC genotype had 1.65- to 3.21-fold higher exposures of ", "from": "24899", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ", pravastatin, simvastatin, lovastatin and atorvastatin than"}, {"to": "25475", "prefix": "nto the bile. BCRP polymorphisms have been associated with ", "from": "25464", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ", atorvastatin, fluvastatin and simvastatin lactone "}, {"to": "25773", "prefix": " polymorphisms, the results of the eltrombopag-", "from": "25762", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " interaction study may be extended to other statins. In subj"}, {"to": "25891", "prefix": "tins. In subjects who were co-administered eltrombopag and ", "from": "25880", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ", increased rosuvastatin Cmax "}, {"to": "25915", "prefix": "re co-administered eltrombopag and rosuvastatin, increased ", "from": "25904", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " Cmax "}, {"to": "26450", "prefix": " appropriate drug selection and dosing [5].\n\nThe impact of ", "from": "26439", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " on plasma eltrombopag PK was not formally assessed. However"}, {"to": "26598", "prefix": "ugh concentrations collected prior to co-administration of ", "from": "26587", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " were similar to trough concentrations collected 24 h after "}, {"to": "26708", "prefix": "collected 24 h after co-administration of a single dose of ", "from": "26697", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ". In addition, plasma eltrombopag exposure for the 75 mg onc"}, {"to": "26834", "prefix": "in combination with a single dose of ", "from": "26823", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": ""}, {"to": "27022", "prefix": "efore, there does not appear to be a significant impact of ", "from": "27011", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " on plasma eltrombopag PK.\n\nPlasma eltrombopag exposures col"}, {"to": "27120", "prefix": "\nPlasma eltrombopag exposures collected in the presence of ", "from": "27109", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " were similar between Asian and non-Asian subjects. This is "}, {"to": "28255", "prefix": "conclusion, concomitant administration of eltrombopag with ", "from": "28244", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " was associated with increased rosuvastatin exposure. The th"}, {"to": "28298", "prefix": "ltrombopag with rosuvastatin was associated with increased ", "from": "28287", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "PMC3162661", "exact": "rosuvastatin", "suffix": " exposure. The therapeutic index of HMG Co-A reductase inhib"}, {"to": "315", "prefix": "suvastatin and inhibition of this transporter could reduce ", "from": "305", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": "-lowering efficacy and increase the risk of exposure-depende"}, {"to": "2138", "prefix": "centrations. Inhibition of these transporters could change ", "from": "2128", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": "-lowering efficacy and increase the risk of exposure-depende"}, {"to": "4598", "prefix": " ", "from": "4588", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": " in subjects receiving rosuvastatin therapy [10].\n\nRosuvasta"}, {"to": "19987", "prefix": "tant for rosuvastatin disposition. Statins are widely used ", "from": "19977", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2438", "setId": "PMC3162661", "exact": "cholesterol", "suffix": "-lowering agents [13] and are generally used as chronic ther"}, {"to": "4752", "prefix": "r-mediated drug interactions, such as its interaction with ", "from": "4742", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015248", "setId": "PMC3162661", "exact": "gemfibrozil", "suffix": " and cyclosporin [11, 12]. The objective of this study was t"}, {"to": "4768", "prefix": "interactions, such as its interaction with gemfibrozil and ", "from": "4758", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016572", "setId": "PMC3162661", "exact": "cyclosporin", "suffix": " [11, 12]. The objective of this study was to evaluate the i"}, {"to": "24923", "prefix": "e had 1.65- to 3.21-fold higher exposures of rosuvastatin, ", "from": "24913", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC3162661", "exact": "pravastatin", "suffix": ", simvastatin, lovastatin and atorvastatin than those with t"}, {"to": "25562", "prefix": ", but not ", "from": "25552", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "PMC3162661", "exact": "pravastatin", "suffix": " or pitavastatin [8, 9, 18, 19].\n\nGiven that exposures to se"}, {"to": "24936", "prefix": "o 3.21-fold higher exposures of rosuvastatin, pravastatin, ", "from": "24926", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3162661", "exact": "simvastatin", "suffix": ", lovastatin and atorvastatin than those with the homozygous"}, {"to": "25518", "prefix": "ssociated with rosuvastatin, atorvastatin, fluvastatin and ", "from": "25508", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "PMC3162661", "exact": "simvastatin", "suffix": " lactone "}, {"to": "24948", "prefix": "igher exposures of rosuvastatin, pravastatin, simvastatin, ", "from": "24939", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "PMC3162661", "exact": "lovastatin", "suffix": " and atorvastatin than those with the homozygous 521TT "}, {"to": "24965", "prefix": " of rosuvastatin, pravastatin, simvastatin, lovastatin and ", "from": "24954", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3162661", "exact": "atorvastatin", "suffix": " than those with the homozygous 521TT "}, {"to": "25489", "prefix": "BCRP polymorphisms have been associated with rosuvastatin, ", "from": "25478", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "PMC3162661", "exact": "atorvastatin", "suffix": ", fluvastatin and simvastatin lactone "}, {"to": "25060", "prefix": " genotypes [6, 16, 17]. In contrast, ", "from": "25050", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3162661", "exact": "fluvastatin", "suffix": " exposure was not different among the T521C genotypes, furth"}, {"to": "25183", "prefix": ", further suggesting that OATP1B1 may not be important for ", "from": "25173", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3162661", "exact": "fluvastatin", "suffix": " disposition. BCRP is highly expressed on the apical membran"}, {"to": "25502", "prefix": "isms have been associated with rosuvastatin, atorvastatin, ", "from": "25492", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "PMC3162661", "exact": "fluvastatin", "suffix": " and simvastatin lactone "}, {"to": "25578", "prefix": ", but not pravastatin or ", "from": "25567", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "PMC3162661", "exact": "pitavastatin", "suffix": " [8, 9, 18, 19].\n\nGiven that exposures to several HMG-CoA re"}]